Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer

Sponsor
Henan Cancer Hospital
Study ID
NCT05547737
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Cross - line treatment of Camrelizumab in non-small cell lung cancer

Study Details

To explore the effectiveness and safety of Camrelizumab based cross-line therapy for patients with advanced NSCLC in the real world

Key Dates

Start date
Sep 21, 2022
Status verified
May 2022
Primary completion
Sep 21, 2025
Completion
Sep 21, 2025

Study Design

Enrollment
500 participants (estimated)

Primary Outcome Measure

Objective Response Rate (ORR) in second-line treatment of patients with non-small cell lung cancer based on Camrelizumab regimen [ Time Frame: Up to 12 months ]

Central Contacts

Related Studies